Among approximately 1000 adenoviruses from chimpanzees and bonobos studied recently, the Pan Adenovirus type 3 (PanAd3, isolated from a bonobo, Pan paniscus) has one of the best profiles for a vaccine vector, combining potent transgene immunogenicity with minimal pre-existing immunity in the human population. In this study, we inserted into a replication defective PanAd3 a transgene expressing a fusion protein of conserved influenza antigens nucleoprotein (NP) and matrix 1 (M1). We then studied antibody and T cell responses as well as protection from challenge infection in a mouse model. A single intranasal administration of PanAd3-NPM1 vaccine induced strong antibody and T cell responses, and protected against high dose lethal influenza virus challenge. Thus PanAd3 is a promising candidate vector for vaccines, including universal influenza vaccines.
Citation: Vitelli A, Quirion MR, Lo C-Y, Misplon JA, Grabowska AK, Pierantoni A, et al. (2013) Vaccination to Conserved Influenza Antigens in Mice Using a Novel Simian Adenovirus Vector, PanAd3, Derived from the Bonobo Pan paniscus. PLoS ONE 8(3): e55435. https://doi.org/10.1371/journal.pone.0055435
Editor: Moriya Tsuji, Aaron Diamond AIDS Research Center with the Rockefeller University, United States of America
Received: July 19, 2012; Accepted: December 23, 2012; Published: March 11, 2013
This is an open-access article, free of all copyright, and may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose. The work is made available under the Creative Commons CC0 public domain dedication.
Funding: Research funding was provided by Okairòs and by CBER, FDA. Authors from Okairòs are employees of and/or shareholders in Okairòs, which is developing vectored vaccines for malaria and other diseases. All decisions concerning study design, data collection and analysis, decision to publish, and preparation of the manuscript were those of the authors, with concurrence of all authors.
Competing interests: The authors have the following interests: Authors from Okairòs are employees of and/or shareholders in Okairòs, which is developing vectored vaccines for malaria and other diseases. Okairòs is developing adenovirus based vaccines for influenza. This research was carried out under a collaborative agreement between CBER, FDA and Okairòs. There are no other patents, products in development or marketed products to declare. This does not alter the authors' adherence to all the PLOS ONE policies on sharing data and materials.
Influenza continues to pose a global health problem, as highlighted by the 2009 swine influenza pandemic and sporadic human infections with avian H5N1 influenza viruses. Antigenic changes in influenza virus, primarily in the surface antigens hemagglutinin (HA) and neuraminidase (NA), are referred to as antigenic shift (subtype changes by reassortment) and antigenic drift (mutation). This variability among influenza viruses hinders vaccination efforts. Currently, annual surveillance is necessary to identify circulating viral strains for use in vaccine production. New vaccines are often required, and take about 6 months to become available . Thus new approaches are needed.
In contrast, so-called “universal” vaccines targeting relatively conserved components of influenza virus can provide protection regardless of strain or subtype of virus, and may provide an alternative to the use of traditional vaccines. This immunity to conserved antigens would not necessarily prevent infection completely, but might decrease severity of disease, speed up viral clearance, and reduce morbidity and mortality during the initial stages of an outbreak until strain-matched vaccine became available . Furthermore, vaccines based on T cell immunity could be used in combination with a seasonal vaccine to improve efficacy, especially in the elderly who are at high risk of severe disease and show reduced responses to current flu vaccines.
Peptide scanning of T cell responses of healthy human individuals has shown that matrix 1 (M1) and nucleoprotein (NP) are among the prominent targets of CD8+ and CD4+ T cell cross-recognition , so they are of interest as vaccine candidates. By sequence homology, NP is >90% conserved among influenza A isolates . Both murine  and human  cytotoxic T lymphocytes induced by NP of one virus strain have been shown to cross-react with NP from different influenza A strains. The strong immune responses to NP in mice contribute to protection against challenge  via CD8+ T cells , , as well as contributions from CD4+ cells ,  and antibodies –. The influenza A matrix (M) gene encodes two highly conserved proteins: an ion channel protein, M2, and the capsid protein, M1. M1 is not a major protective antigen in the mouse and is not well recognized by mouse T cells , but has long been known to be recognized by human T cells . Thus its potential contribution to vaccine protection may be underestimated by mouse studies.
While epitopes providing targets widely shared among influenza viruses have been identified in multiple viral proteins, not all of them are highly immunogenic when presented by classical vaccines. More potent immunization can be achieved using recombinant vectors to express the influenza antigens and focus immunity on these targets. Recombinant adenovirus vectors are especially effective at eliciting strong T cell responses to transgene products –. Recombinant adenovirus vectors expressing NP  or both NP and M2 ,  can protect mice against a range of influenza virus challenges, including highly pathogenic avian H5N1 strains. While potential interference by prior immunity to human adenoviruses has been suggested as a barrier, this issue can be circumvented by use of vectors based on animal adenoviruses –. Chimpanzee adenoviruses have been shown to be useful vaccine vectors in a variety of animal studies –, and the prevalence of neutralizing antibodies against chimpanzee adenoviruses is low in human populations –, but not all of them are equally immunogenic.
In this study, we use a simian adenovirus, PanAd3, isolated from the bonobo Pan paniscus. This novel adenovirus strain was identified in a study of more than 1000 adenoviruses isolated from chimpanzees and bonobos in order to increase the available repertoire of vectors . In the large scale screening experiments, PanAd3 was among the most potently immunogenic in mice and was also among the least frequently recognized by neutralizing antibodies in human sera.
We have generated a replication incompetent PanAd3 vector deleted of E1 and E3 regions and expressing a fusion protein of the NP and M1 antigens of influenza A, chosen as targets of broad and cross-reactive T cell immunity in humans . The PanAd3-based vaccine was tested for induction of antibody and T cell responses in the systemic and mucosal compartments in mice, as well as for protection against lethal influenza virus challenge. We demonstrate that PanAd3 expressing conserved influenza virus antigens provided highly effective protection after a single intranasal administration. Thus it shows considerable promise as a vaccine candidate.
Materials and Methods
All animal protocols and procedures were approved by the Institutional Animal Care and Use Committee at the Center for Biologics Evaluation and Research (protocol #1991-06) and conducted in an SPF animal facility accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. All experiments were performed according to institutional guidelines. During influenza challenge studies, animals that had lost 25% of their initial body weight were humanely euthanized to avoid further suffering.
Highly virulent, mouse-adapted virus A/Fort Monmouth/1/47-ma (H1N1) [A/FM] has been previously described  and was kindly provided by Earl Brown, University of Ottawa, Canada. It was prepared as a pooled homogenate of lungs from BALB/c mice infected with the virus by the intranasal (i.n.) route 4 days earlier.
Pan Adenovirus type 3 (PanAd3) was isolated from a stool specimen collected from a bonobo (Pan paniscus). The PanAd3 isolate was amplified and the virus genome was then cloned in a plasmid vector and fully sequenced. As shown in a phylogenetic tree based on hexon sequences , PanAd3 is a member of adenovirus species C, closely related to species C human and chimpanzee adenoviruses already used in preclinical and clinical trials (human Ad5, ChAd3).
PanAd3 vectors were constructed by homologous recombination in E. coli strain BJ5183 by co-transformation with PanAd3 purified viral DNA and a PanAd3-EGFP shuttle vector. Homologous recombination between pIX genes, right ITR DNA sequences present at the ends of linearized PanAd3-EGFP shuttle and viral genomic DNA allowed its insertion in the plasmid vector, simultaneously replacing the E1 region with a human cytomegalovirus (HCMV) promoter-driven EGFP expression cassette containing the bovine growth hormone polyadenylation signal (BGH polyA), generating pPanAd3ΔE1-EGFP. The E3 region (nucleotides 28684 to 32640) was then deleted through several cloning and homologous recombination steps to generate the pPanAd3ΔE1ΔE3 backbone, which was propagated in HEK 293 cells.
Expression cassettes containing consensus sequences of NP and M1 plus the human cytomegalovirus promoter and bovine growth hormone polyadenylation signal were constructed. The influenza expression cassette contains consensus sequences of NP and M1. Influenza A NP and M1 sequences were obtained from the NCBI Influenza Virus Resource database (http://www.ncbi.nlm.nih.gov/genomes/FLU/FLU.html). Protein sequences were chosen from among different subtype strains isolated between 1990 and 2009 that caused infection in humans worldwide. The NP consensus sequence was derived by alignment of all non-identical sequences (H1N1: 88 of 629 sequences, H1N2: 5 of 26, H3N2: 244 of 1557, H5N1: 50 of 121) using MUSCLE version 3.6, and applying the majority rule. Further, the NP sequence used in the PanAd3 vaccine lacks the Nuclear Localization Signal residing in aa 6–8 (TKR mutated to AAA), which results in increased cytoplasmic accumulation. The M1 consensus sequence was similarly derived by the alignment of non-identical sequences (H1N1: 51 of 808 sequences, H1N2: 3 of 34, H3N2: 115 of 2150, H5N1: 23 of 145). NP and M1 sequences were spaced by a flexible linker (GGGSGGG). The resulting NPM1 sequence was codon-optimized for expression in eukaryotic cells. A diagram of the insert and its full sequence are given in Figure 1. The NPM1 expression cassette was inserted into the PanAd3ΔE1ΔE3 backbone via homologous recombination in E.coli. Sequences for HIV gag protein or a respiratory syncytial virus (RSV) fusion protein of F protein, nucleoprotein N and transcription factor M2-1 were inserted in constructs to be used as specificity controls. Expression cassettes were inserted into a pNEB shuttle vector and then transferred into the SnaBI linearized pPanAd3ΔE1ΔE3-EGFP plasmid by homologous recombination in E. coli, exploiting the homology between the HCMV promoter and BGH polyA sequences. The PanAd3 vectors were produced in Procell 92 cells, which were derived from the HEK 293 cell line originally banked at the University of Leiden in 1973  and obtained from Frank Graham at MacMaster University (Hamilton, Canada), and further adapted at Okairòs to be suitable for manufacturing by incorporation of a plasmid carrying a Tet repressor expression cassette and G418-resistance gene. The protocol for generating the Procell 92 cell line followed essentially that published by Matthews et al. . Briefly, HEK 293 cells were transfected with an expression vector containing a cassette encoding the Tet repressor under control of the human phosphoglycerate kinase-1 (PGK) promoter, and the G418-resistance gene. Single clones were selected by growing the transfected cells in the presence of 1 mg/ml G418 in culture medium. Single clones were amplified and tested for Tet repressor expression by Western Blot analysis. The stability of Tet repressor expression in the selected clone was tested up to passage 63. PanAd3 vectors grown in these cells were purified by cesium chloride gradients and stored in buffer A195 .
a) Design of the insert showing CMV promoter, NPM1 transgene, and BGH-polyadenylation cassettes. b) Complete amino acid sequence of the consensus NPM1 fusion protein. NP is indicated in red, linker sequence is shown in black, and M1 is green. The deletion of the nuclear localization signal by mutation of TKR to AAA in NP is indicated in bold text.
Viral particle (vp) measurements of adenovirus stocks were made by measurement of absorbance at 260 nm as described .
Peptides and proteins
Peptides NP147–155 (TYQRTRALV) and SARS M209–221 (HAGSNDNIALLVQ) were synthesized by the CBER core facility. An MHC-I restricted peptide of adenovirus DNA-binding protein (Dbp419–427: FALSNAEDL), present in PanAd3  and recombinant M1 (rM1) protein from strain A/PR/8/34 (H1N1) were purchased from Genscript (Piscataway, NJ). Recombinant nucleoprotein (rNP) from strain A/PR/8/34 (H1N1) was purchased from Imgenex (San Diego, CA).
In vitro expression and Western blot (WB)
HeLa cells were infected with PanAd3-NPM1 at indicated multiplicities of infection (MOI). Extracts were prepared 48 hours after infection using TEN buffer (20 mM Tris pH 7.5, 150 mM NaCl, 1 mM EDTA pH 8, 1% Triton X100 and protease inhibitors). Nuclei and cell debris were spun out by centrifugation at 7,500 g, 30 minutes at 4°C. Glycerol was added to supernatants to 10% and stored at −20°C. Expression was assessed by Western blotting with a mouse hyperimmune serum raised against the NPM1 antigen.
Mouse immunization and challenge infection
Female BALB/cAnNCr mice aged 5–7 weeks were purchased from the National Cancer Institute, Frederick, MD. Inoculations were performed by administration of 50 µl vaccine or challenge virus given i.n. while mice were under isoflurane anesthesia, or by administration of 100 µl of vaccine by intramuscular (i.m.) injection. Mice were immunized at 10 weeks of age with indicated doses. Some groups of mice were challenged 4 weeks post-immunization under isoflurane anesthesia with 104 TCID50 (100 LD50) of A/FM.
Mice were euthanized and bronchoalveolar lavage (BAL) fluid and lung cells obtained as in Price et al., 2009 . Briefly, for BAL fluid, lungs were flushed with 1 ml phosphate-buffered saline (PBS). Lung cells were isolated by gradient centrifugation of minced and collagenase-digested lung tissue.
Spleen and blood sampling
Splenocytes were depleted of erythrocytes by treatment with ACK lysis buffer. Sera from blood collected from the abdominal vena cava were isolated using BD Microtainers (Franklin Lakes,NJ), and decomplemented by heat-treating at 56°C for 30 minutes.
T cell ELISPOT
T cell ELISPOT assays were performed as described previously . Briefly, anti–interferon (IFN)-γ mAb AN18 (BD Pharmingen, San Jose, CA) was used to coat ELISPOT plates (Millipore, Billerica, MA). Splenocytes or lung cells were added to wells at a concentration of 250,000 cells/well (and, when necessary, also 62,500 cells/well to bring results into the countable range) in CT medium . Peptides were added at a final concentration of 1 µg/ml. Plates were incubated for 36–48 hr at 37°C in 5% CO2. Bound IFN-γ was detected with biotinylated mAb R4–6A2 (BD Pharmingen) followed by incubation with alkaline phosphatase–labeled streptavidin (KPL, Gaithersburg, MD). 100 µl 5-bromo, 4-chloro, 3-indolylphosphate/nitroblue tetrazolium was used as the developing substrate (KPL). Spots were counted with an ELISPOT reader (Zeiss; Thornwood, NY).
Antibody levels in serum and BAL were measured by enzyme-linked immunosorbent assay (ELISA) as in Benton et al. . Specifically, NUNC 96-well plates were coated at 4°C overnight with 1 µg/ml of rNP or 5 µg/ml of rM1 in PBS, then blocked. Next individual mouse sera or BAL were added to the plates. Bound antibody was detected using human-adsorbed alkaline phosphatase-conjugated goat anti-mouse IgG, or IgA (Southern Biotechnology Associates, Birmingham, AL) followed by the substrate p-nitrophenyl phosphate (Sigma). OD was measured at 405 nm.
Neutralizing antibody assay
Ad5 and PanAd3 neutralizing antibody titers were assayed as previously described  with some modifications. Briefly, 3.5×104 HEK293 cells per well were seeded in a 96 well plate and cultured for 2 days. Each adenoviral vector expressing secreted alkaline phosphatase (SeAP) was incubated for 1 hour at 37°C alone or with serial dilutions of serum, and then added to the 95–100% confluent HEK293 cells and incubated for 1 hour at 37°C. Supernatant was then removed and replaced with 10% FCS in DMEM. SeAP expression was measured 24 hours later using the chemiluminescent substrate (CSPD), from the Phospha-LightTM kit (Tropix Cat No T1016, Applied Biosystems, Bedford, MA) without heat inactivation. Light emission (relative light units, RLU) was monitored 45 minutes after the addition of the CSPD substrate, using the Envision 2102 Multi-label reader (Perkin Elmer, Waltham, MA).
Expression of influenza proteins from PanAd3 vectors
The PanAd3-NPM1 construct was designed using two conserved influenza antigens important in human immunity, NP and M1. To analyze the level of transgene expression, HeLa cells were infected with PanAd3-NPM1 at various MOI, and Triton extracts prepared. Western blot analysis of the extracts was performed using a mouse hyperimmune serum raised against the NPM1 antigen. The 80 kD major band seen is consistent with the fusion NPM1 protein (Fig. 2). The 80 kD band was also detected if the Western blot was developed with a monoclonal antibody to NP (data not shown).
Western blot analysis of HeLa extracts prepared as described after 48 hours infection with PanAd3NPM1 at 50, 250, 1250 MOI (ni = not infected). The blotted proteins were revealed with a mouse hyperimmune serum raised against the NPM1 antigen. The 80 kD major band is consistent with the fusion NPM1 protein.
Immune responses to PanAd3-NPM1, comparing i.m. and i.n. routes
Intranasal (i.n.) immunization is especially efficient for induction of local immunity in the respiratory tract, including recruitment of memory T cells to the airways . For a given vaccination, i.n. induces greater mucosal immune responses than intramuscular (i.m.) immunization, but weaker systemic responses , . In pilot studies, we included both routes of immunization, in order to characterize the responses induced by the new vector.
Sera from individual mice 4 weeks after immunization were tested for antibodies to NP. As shown in Figure 3A, equivalent IgG responses to NP were detected in serum responses to PanAd3-NPM1 given either i.m. or i.n. at a dose of 109 viral particles (vp). Serum antibody responses were reduced when animals were immunized with a lower dose (107 vp) of PanAd3-NPM1. In the BAL, anti-NP IgG antibodies were induced by i.n. but not i.m. immunization (Fig. 3B). PanAd3-NPM1 induced very little IgA in the BAL (Fig. 3C). A reagent control provided by BAL from A/NP+M2-rAd5 immunized mice, a system known from previous studies to induce IgA , showed that the assay could detect IgA antibodies if present.
Mice were vaccinated with 109 or 107 total vp/mouse. Immunizations were by either the i.n. or i.m. route, as indicated. Four weeks later mice were sacrificed, and serum and BAL were collected for antibody analysis. Lung T cells were also collected for IFN-γ ELISPOT analysis. Error bars indicate mean ± SEM. a) ELISA for IgG antibodies to rNP in the serum. b) ELISA for IgG antibodies to rNP in the BAL. c) ELISA for IgA antibodies to rNP in the BAL. d) ELISPOT for IFN-γ T cell responses. Results for three mice per group are reported as number of IFN-γ secreting cells per 106 cells. Black bars, stimulation with NP147–155 peptide. Gray bars, stimulation with SARS209–221 peptide. Top: T cells in the lungs. Bottom: T cells in the spleen. Bars show mean ± SEM of pooled group triplicates, not individual animals.
T cell responses.
Functional T cell responses to vaccination were measured by IFN-γ ELISPOT. Figure 3D shows responses in the spleen and lungs to NP147–155 peptide, the immunodominant MHC I epitope of CD8+ T cells in BALB/c mice . Immunization with PanAd3-NPM1 i.m. produced much higher frequencies of NP-specific T cells in the spleen than i.n. immunization, while the reverse was true in the lungs. These results show anatomical localization of the immune response, with i.n. more efficiently priming T cells in the respiratory tract, consistent with previous studies , , . No response to NP was seen in mice immunized with constructs containing an irrelevant transgene (HIV gag), and none of the mice responded to the SARS209–221 control peptide.
A pilot experiment showed protection against challenge four weeks post-vaccination with 109 vp of PanAd3-NPM1 given i.n. (data not shown). Thus the PanAd3 vector was promising, and we pursued more detailed studies.
Detailed characterization of immune responses to mucosally administered PanAd3 recombinant
Given the superiority of i.n. administration for inducing T cell responses in the lungs, we further explored the immune responses to vaccination by this mucosal route, using PanAd3-NPM1 or as a control PanAd3 with an irrelevant RSV insert. Mice were immunized with doses of 109,107, or 105 vp per mouse.
Serum and BAL were analyzed for IgG and IgA antibodies to NP and M1. Figure 4A shows results for IgG antibodies to NP in serum and BAL. At the highest vaccine dose, 109 vp per mouse, strong IgG responses were seen for PanAd3-NPM1. If the vaccine dose given to the mice was reduced to 107 vp per mouse, antibody responses were greatly reduced in serum and absent in BAL.
Mice were vaccinated with indicated doses. Four weeks later mice were sacrificed, and serum and BAL were collected for antibody analysis. Error bars indicate mean ± SEM. a) ELISA for IgG antibodies to rNP in the serum and BAL. b) ELISA for IgA antibodies to rNP in the serum and BAL. c) ELISA for IgG antibodies to rM1 in the serum and BAL.
The IgA antibody response to PanAd3-NPM1 was undetectable in serum and marginal in BAL (Fig. 4B). As in Figure 3, a reagent control provided by BAL from A/NP-rAd5 immunized mice showed that the assay could detect IgA antibodies if present. The antibody response to the M1 component of PanAd3-NPM1 did not include IgA (data not shown) and the IgG response to M1 was only substantial in the serum (Fig. 4C).
T cell responses.
T cell responses were again measured by IFN-γ ELISPOT. At a dose of 109 vp, PanAd3-NPM1 induced a strong T cell response in the lungs to the dominant NP147–155 epitope. Both PanAd3-NPM1 and the PanAd3-RSV control induced modest responses to the adenovirus peptide Dbp419–427 (Fig. 5). A hundred-fold lower dose of PanAd3-NPM1 induced little response to either NP147–155 or Dbp419–427.
Mice were immunized as in Figure 3. Four weeks post-immunization, T -cells of three mice per group were assayed by IFN-γ ELISPOT. Results shown are for lung T cells, and are reported as number of IFN-γ secreting cells per 106 cells. Bars show mean ± SEM of results for lungs of individual mice.
Immune protection against challenge infection.
One month after immunization mice were challenged with 100 LD50 (104 TCID50) of A/FM, a relatively high dose of a highly pathogenic virus. As shown in Figure 6, a dose of 107 vp or less did not protect, but at a dose of 109 vp PanAd3-NPM1 provided considerable protection against this stringent challenge. Most mice survived and displayed much less morbidity than controls, as shown by weight loss.
Mice were immunized as in Figure 3. Approximately 9 weeks post-immunization, mice were challenged with influenza virus A/FM at a dose of 104 TCID50 (100 LD50) per mouse, and monitored for body weight and mortality. Survival of the PanAd3-NPM1 group at the dose of 109 vp differs significantly (p<0.05) from the PanAd3-RSV control group. Error bars indicate mean ± SEM.
Cross-neutralization by human antibodies to Ad5.
Ad5 and PanAd3 are closely related viruses, both belonging to adenovirus group C . As one aspect of whether PanAd3 vectors are likely to be blocked by pre-existing immunity to Ad5, we tested neutralization of a PanAd3 virus by human sera selected for particularly high neutralizing antibody to Ad5 (titers >1000). As shown in Table S1, many of these high-titered sera had no neutralizing activity on PanAd3. Some of the human sera with very high neutralizing titers ranging from 1628 to 4608 on Ad5 had low neutralizing titers of 28–63 on PanAd3.
In the efforts to develop a universal influenza vaccine, various platforms for immunization to conserved antigens have been studied. Replication incompetent adenovirus vectors are promising, since their strong induction of innate immune responses provides a built-in adjuvant, and the antigen-specific B and T cell responses they induce are sustained for a long time . Animal adenoviruses have the potential advantage that humans have no prior exposure to them. For that reason chimpanzee adenoviruses have recently begun to be explored for use as vaccine vectors in humans, where they showed good safety and excellent immunogenicity , , . Furthermore, in tests of Ad5 and four chimpanzee adenovirus vectors, prior immunization with a GFP-expressing construct blocked subsequent responses to the transgene product only for homologous vector; cross-blocking was minimal .
In this study, we tested a new vector based on bonobo virus PanAd3. Both Ad5 and bonobo virus PanAd3 belong to the adenovirus species C . Species B (for example Ad35) has been shown in other studies to be less immunogenic than species C . Since they are so closely related, Ad5 and PanAd3 may share certain structural features providing powerful internal adjuvant effects and thus higher immunogenicity. Despite the structural similarity, human sera containing high anti-Ad5 neutralization titers (>1000) show no or marginal neutralization capacity on PanAd3. Moreover, in a screening study, PanAd3 was shown to be a potent vector in mice and in primates . We show here that a single administration of PanAd3-NPM1 influenza vaccine given i.n. provided highly effective protection against lethal challenge with mouse-adapted A/FM, with greatly reduced morbidity and mortality compared to controls. Protection was comparable to that in previously published studies of Ad5 expressing conserved influenza virus antigens for the same challenge virus and dose , .
The PanAd3 vaccine induced both antibody and T cell responses to NP. As mentioned earlier, the T cell response to NP is well-known to contribute to protection , –, and recent studies have reported that antibodies to NP can also contribute to protection .
The fusion protein of NP with M1 expressed by the PanAd3 vaccine has the advantage of including another major target of human immunity. Using multiple target antigens may invoke different immune mechanisms, reduce the likelihood of generating escape mutants, and provide a larger range of epitopes that may be suitable for different MHC types. Although M1 is not expected to play much of a role in protection in mice, it is a prominent target of T cell immunity in humans , and might contribute to the performance of the PanAd3-NPM1 vaccine in humans.
The results presented here support the use of the PanAd3 vector as a vaccine candidate that is highly effective at inducing T cell and antibody immunity, while at the same time having the advantage that it is not neutralized by human sera . Thus PanAd3, when used to express conserved influenza virus antigens, has promise as a “universal” influenza vaccine candidate.
Sera from healthy human individuals from different geographical areas in Europe and the United States had been screened previously for neutralizing activity to Ad5 . Selected sera with high Ad5 neutralizing activity (titers >1000) were tested for neutralization of PanAd3 as described in Materials and Methods, using vectors expressing the secreted alkaline phosphatase (SeAP) reporter gene. * Arbitrary sample numbers. ** Results of two tests. Ethics statement: All volunteers gave written informed consent before participation, and the studies were conducted according to the principles of the Declaration of Helsinki and in accordance with Good Clinical Practice.
We thank Anthony Ferrine, Mary Belcher and the CBER animal facility staff for care of experimental animals, and Marian Major and Andrew Byrnes for review of the manuscript.
Conceived and designed the experiments: AN SLE AV MRQ C-YL JAM GEP. Performed the experiments: AV MRQ C-YL JAM GEP MRS AP AKG. Analyzed the data: AV MRQ C-YL JAM GEP MRS SLE AN. Contributed reagents/materials/analysis tools: AKG AP VA SC RC. Wrote the paper: SLE GEP AV MRQ C-YL JAM RC.
- 1. Gerdil C (2003) The annual production cycle for influenza vaccine. Vaccine 21: 1776–1779.
- 2. Epstein SL, Price GE (2010) Cross-protective immunity to influenza A viruses. Expert Rev Vaccines 9: 1325–1341 10.1586/erv.10.123.
- 3. Lee LY, Ha DLA, Simmons C, de Jong MD, Chau NV, et al. (2008) Memory T cells established by seasonal human influenza A infection cross-react with avian influenza A (H5N1) in healthy individuals. J Clin Invest 118: 3478–3490.
- 4. Altmüller A, Fitch WM, Scholtissek C (1989) Biological and genetic evolution of the nucleoprotein gene of human influenza A viruses. J Gen Virol 70: 2111–2119.
- 5. Townsend ARM, McMichael AJ, Carter NP, Huddleston JA, Brownlee GG (1984) Cytotoxic T cell recognition of the influenza nucleoprotein and hemagglutinin expressed in transfected mouse L cells. Cell 39: 13–25.
- 6. Boon ACM, de Mutsert G, van Baarle D, Smith DJ, Lapedes AS, et al. (2004) Recognition of homo- and heterosubtypic variants of influenza A viruses by human CD8+ T lymphocytes. J Immunol 172: 2453–2460.
- 7. Ulmer JB, Fu T-M, Deck RR, Friedman A, Guan L, et al. (1998) Protective CD4+ and CD8+ T cells against influenza virus induced by vaccination with nucleoprotein DNA. J Virol 72: 5648–5653.
- 8. Yewdell JW, Bennink JR, Smith GL, Moss B (1985) Influenza A virus nucleoprotein is a major target antigen for cross-reactive anti-influenza A virus cytotoxic T lymphocytes. Proc Natl Acad Sci USA 82: 1785–1789.
- 9. Graham MB, Braciale TJ (1997) Resistance to and recovery from lethal influenza virus infection in B lymphocyte-deficient mice. J Exp Med 186: 2063–2068.
- 10. Epstein SL, Stack A, Misplon JA, Lo C-Y, Mostowski H, et al. (2000) Vaccination with DNA encoding internal proteins of influenza virus does not require CD8+ CTL: Either CD4+ or CD8+ T cells can promote survival and recovery after challenge. Intl Immunol 12: 91–101.
- 11. Carragher DM, Kaminski DA, Moquin A, Hartson L, Randall TD (2008) A novel role for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza virus. J Immunol 181: 4168–4176.
- 12. Lamere MW, Lam HT, Moquin A, Haynes L, Lund FE, et al. (2011) Contributions of antinucleoprotein IgG to heterosubtypic immunity against influenza virus. J Immunol 186: 4331–4339 jimmunol.1003057;10.4049/jimmunol.1003057.
- 13. Lamere MW, Moquin A, Lee FE, Misra RS, Blair PJ, et al. (2011) Regulation of antinucleoprotein IgG by systemic vaccination and its effect on influenza virus clearance. J Virol 85: 5027–5035 JVI.00150-11;10.1128/JVI.00150-11.
- 14. Yewdell JW, Hackett CJ (1989) Specificity and function of T lymphocytes induced by influenza A viruses. In: Krug RM, editors. The Influenza Viruses. Plenum Publishing Corp. pp. 361–429.
- 15. Gotch F, McMichael A, Smith G, Moss B (1987) Identification of viral molecules recognized by influenza-specific human cytotoxic lymphocytes-T. J Exp Med 165: 408–416.
- 16. Xiang ZQ, Yang Y, Wilson JM, Ertl HC (1996) A replication-defective human adenovirus recombinant serves as a highly efficacious vaccine carrier. Virol 219: 220–227 S0042-6822(96)90239-1 [pii];10.1006/viro.1996.0239 [doi].
- 17. Santra S, Seaman MS, Xu L, Barouch DH, Lord CI, et al. (2005) Replication-defective adenovirus serotype 5 vectors elicit durable cellular and humoral immune responses in nonhuman primates. J Virol 79: 6516–6522.
- 18. Sumida SM, Truitt DM, Kishko MG, Arthur JC, Jackson SS, et al. (2004) Neutralizing antibodies and CD8+ T lymphocytes both contribute to immunity to adenovirus serotype 5 vaccine vectors. J Virol 78: 2666–2673.
- 19. Epstein SL, Kong WP, Misplon JA, Lo C-Y, Tumpey TM, et al. (2005) Protection against multiple influenza A subtypes by vaccination with highly conserved nucleoprotein. Vaccine 23: 5404–5410.
- 20. Price GE, Soboleski MR, Lo CY, Misplon JA, Pappas C, et al. (2009) Vaccination focusing immunity on conserved antigens protects mice and ferrets against virulent H1N1 and H5N1 influenza A viruses. Vaccine 27: 6512–6521.
- 21. Price GE, Soboleski MR, Lo CY, Misplon JA, Quirion MR, et al. (2010) Single-dose mucosal immunization with a candidate universal influenza vaccine provides rapid protection from virulent H5N1, H3N2 and H1N1 viruses. PLoS ONE 5: e13162 10.1371/journal.pone.0013162.
- 22. Kremer EJ, Boutin S, Chillon M, Danos O (2000) Canine adenovirus vectors: an alternative for adenovirus-mediated gene transfer. J Virol 74: 505–512.
- 23. Mittal SK, Middleton DM, Tikoo SK, Babiuk LA (1995) Pathogenesis and immunogenicity of bovine adenovirus type 3 in cotton rats (Sigmodon hispidus). Virol 213: 131–139 S0042-6822(85)71553-X [pii];10.1006/viro.1995.1553 [doi].
- 24. Roy S, Gao G, Lu Y, Zhou X, Lock M, et al. (2004) Characterization of a family of chimpanzee adenoviruses and development of molecular clones for gene transfer vectors. Hum Gene Ther 15: 519–530 10.1089/10430340460745838 [doi].
- 25. Xu ZZ, Hyatt A, Boyle DB, Both GW (1997) Construction of ovine adenovirus recombinants by gene insertion or deletion of related terminal region sequences. Virol 230: 62–71 S0042-6822(97)98452-X [pii];10.1006/viro.1997.8452 [doi].
- 26. Kobinger GP, Feldmann H, Zhi Y, Schumer G, Gao G, et al. (2006) Chimpanzee adenovirus vaccine protects against Zaire Ebola virus. Virol 346: 394–401 S0042-6822(05)00654-9 [pii];10.1016/j.virol.2005.10.042 [doi].
- 27. Peruzzi D, Dharmapuri S, Cirillo A, Bruni BE, Nicosia A, et al. (2009) A novel chimpanzee serotype-based adenoviral vector as delivery tool for cancer vaccines. Vaccine 27: 1293–1300 S0264-410X(09)00012-7;10.1016/j.vaccine.2008.12.051.
- 28. Reyes-Sandoval A, Sridhar S, Berthoud T, Moore AC, Harty JT, et al. (2008) Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei. Eur J Immunol 38: 732–741 10.1002/eji.200737672 [doi].
- 29. Tatsis N, Tesema L, Robinson ER, Giles-Davis W, McCoy K, et al. (2006) Chimpanzee-origin adenovirus vectors as vaccine carriers. Gene Ther 13: 421–429 3302675 [pii];10.1038/sj.gt.3302675 [doi].
- 30. Zhi Y, Figueredo J, Kobinger GP, Hagan H, Calcedo R, et al. (2006) Efficacy of severe acute respiratory syndrome vaccine based on a nonhuman primate adenovirus in the presence of immunity against human adenovirus. Hum Gene Ther 17: 500–506 10.1089/hum.2006.17.500 [doi].
- 31. Aste-Amezaga M, Bett AJ, Wang F, Casimiro DR, Antonello JM, et al. (2004) Quantitative adenovirus neutralization assays based on the secreted alkaline phosphatase reporter gene: application in epidemiologic studies and in the design of adenovector vaccines. Hum Gene Ther 15: 293–304 10.1089/104303404322886147 [doi].
- 32. Mittereder N, March KL, Trapnell BC (1996) Evaluation of the concentration and bioactivity of adenovirus vectors for gene therapy. J Virol 70: 7498–7509.
- 33. Thorner AR, Lemckert AAC, Goudsmit J, Lynch DM, Ewald BA, et al. (2006) Immunogenicity of heterologous recombinant adenovirus prime-boost vaccine regimens is enhanced by circumventing vector cross-reactivity. J Virol 80: 12009–12016.
- 34. Colloca S, Barnes E, Folgori A, Ammendola V, Capone S, et al. (2012) Vaccine vectors derived from a large collection of simian adenoviruses induce potent cellular immunity across multiple species. Sci Transl Med 4: 115ra2 4/115/115ra2 [pii];10.1126/scitranslmed.3002925 [doi].
- 35. Smeenk CA, Brown EG (1994) The influenza-virus variant A/FM/1/47-MA possesses single amino-acid replacements in the hemagglutinin, controlling virulence, and in the matrix protein, controlling virulence as well as growth. J Virol 68: 530–534.
- 36. Graham FL, Smiley J, Russell WC, Nairn R (1977) Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36: 59–74.
- 37. Matthews DA, Cummings D, Evelegh C, Graham FL, Prevec L (1999) Development and use of a 293 cell line expressing lac repressor for the rescue of recombinant adenoviruses expressing high levels of rabies virus glycoprotein. J Gen Virol 80 (Pt 2) 345–353.
- 38. Evans RK, Nawrocki DK, Isopi LA, Williams DM, Casimiro DR, et al. (2004) Development of stable liquid formulations for adenovirus-based vaccines. J Pharm Sci 93: 2458–2475.
- 39. Smith JS, Tian J, Muller J, Byrnes AP (2004) Unexpected pulmonary uptake of adenovirus vectors in animals with chronic liver disease. Gene Ther 11: 431–438.
- 40. McKelvey T, Tang A, Bett AJ, Casimiro DR, Chastain M (2004) T-cell response to adenovirus hexon and DNA-binding protein in mice. Gene Ther 11: 791–796 10.1038/sj.gt.3302232 [doi];3302232 [pii].
- 41. Tompkins SM, Zhao ZS, Lo C-Y, Misplon JA, Liu T, et al. (2007) Matrix protein 2 vaccination and protection against influenza viruses, including subtype H5N1. Emerg Infect Dis 13: 426–435.
- 42. Zhong WM, Marshall D, Coleclough C, Woodland DL (2000) CD4+ T cell priming accelerates the clearance of Sendai virus in mice, but was a negative effect on CD8+ T cell memory. J Immunol 164: 3274–3282.
- 43. Benton KA, Misplon JA, Lo C-Y, Brutkiewicz RR, Prasad SA, et al. (2001) Heterosubtypic immunity to influenza A virus in mice lacking either IgA, all Ig, NKT cells, or γδ T cells. J Immunol 166: 7437–7445.
- 44. Takamura S, Roberts AD, Jelley-Gibbs DM, Wittmer ST, Kohlmeier JE, et al. (2010) The route of priming influences the ability of respiratory virus-specific memory CD8+ T cells to be activated by residual antigen. J Exp Med 207: 1153–1160 jem.20090283;10.1084/jem.20090283.
- 45. Deng YP, Yewdell JW, Eisenlohr LC, Bennink JR (1997) MHC affinity, peptide liberation, T cell repertoire, and immunodominance all contribute to the paucity of MHC class I- restricted peptides recognized by antiviral CTL. J Immunol 158: 1507–1515.
- 46. Dudareva M, Andrews L, Gilbert SC, Bejon P, Marsh K, et al. (2009) Prevalence of serum neutralizing antibodies against chimpanzee adenovirus 63 and human adenovirus 5 in Kenyan children, in the context of vaccine vector efficacy. Vaccine 27: 3501–3504 S0264-410X(09)00502-7 [pii];10.1016/j.vaccine.2009.03.080 [doi].
- 47. Abbink P, Lemckert AA, Ewald BA, Lynch DM, Denholtz M, et al. (2007) Comparative seroprevalence and immunogenicity of six rare serotype recombinant adenovirus vaccine vectors from subgroups B and D. J Virol 81: 4654–4663 JVI.02696-06 [pii];10.1128/JVI.02696-06 [doi].